Article
Every Disclosed Conflict of Interest at Psychedelic Science 2023
All the financial conflict disclosures from Psychedelics Science 2023 speakers, in one handy list.
Russell Hausfeld is an investigative journalist and illustrator living in Cincinnati, Ohio. He has a Bachelor’s degree in Journalism and Religious Studies from the University of Cincinnati. His work with Psymposia has been cited in Vice, The Nation, Frontiers in Psychology, New York Magazine’s “Cover Story: Power Trip” podcast, the Daily Beast, the Outlaw Report, Harm Reduction Journal, and more.
Article
All the financial conflict disclosures from Psychedelics Science 2023 speakers, in one handy list.
Article
In order to present at Psychedelic Science 2023, speakers must agree to two out-of-the-ordinary requests about content exclusivity and MAPS’ reputation.
Article
The Multidisciplinary Association for Psychedelic Studies (MAPS) quietly replaced founder Rick Doblin as Executive Director with Kris Lotlikar.
Article
Fluence will no longer seek a trademark for the phrase “Psychedelic Harm Reduction and Integration.”
Article
Throughout his lifetime, Robert Friedland has evolved from Steve Jobs’ psychedelic guru to mining guru, leaving a trail of environmental destruction in his wake.
Article
From cultural appropriation to “Shroom Boom,” psychedelic online marketing gaffes and misrepresentations are becoming more and more prevalent from major psychedelic organizations.
Article
A new website — whoisjoeschraube.com — alleges that Joe Schraube and Miguel Delgado have taken advantage of positions of power and abused people under the influence of psychedelics.
Article
DoubleBlind claims its recently-unveiled New York City billboard is a lot of things, except what it actually is: a giant advertisement.
Article
Hamilton Morris, the creator of Vice’s “Hamilton’s Pharmacopeia,” will cease working with Vice on the show following the third season. He has joined psychedelic pharmaceutical corporation COMPASS Pathways as a chemistry consultant.
Article
While COMPASS has issued a response defending the validity of its patents, one of the co-inventors says the patent examiner’s opinion is probably “a valid one.”
Article
The Third Wave copied information from Psychedelic.Support and MAPS Integration List without permission to use for its own directory.
Article
News that COMPASS Pathways is attempting to patent psychedelic therapy room specifications and therapist behaviors started an online firestorm about the company’s “monopolistic and shady behaviors,” but so far the debates have missed the biggest threats lurking in COMPASS’s international patent appl
Psymposia is a research and media 501(c)(3) nonprofit that offers critical perspectives on drugs, politics, and culture. We rely on audience support to keep our work independent and focused on the public interest. You can sustain Psymposia by becoming a member, which includes exclusive content and perks.